| Stereochemistry | ACHIRAL |
| Molecular Formula | C28H28ClF2N3O |
| Molecular Weight | 495.991 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC=C(C=C1)C(CCCN2CCC(CC2)N3C(=O)NC4=C3C=CC(Cl)=C4)C5=CC=C(F)C=C5
InChI
InChIKey=JCZYXTVBWHAWLL-UHFFFAOYSA-N
InChI=1S/C28H28ClF2N3O/c29-21-7-12-27-26(18-21)32-28(35)34(27)24-13-16-33(17-14-24)15-1-2-25(19-3-8-22(30)9-4-19)20-5-10-23(31)11-6-20/h3-12,18,24-25H,1-2,13-17H2,(H,32,35)
| Molecular Formula | C28H28ClF2N3O |
| Molecular Weight | 495.991 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Clopimozide is a typical antipsychotic drug, developed by Janssen Pharmaceutica. Clopimozide belongs to diphenylbutylpiperidine class of neuroleptics, and possess an extremely long duration of action. The drug acts by binding to dopamine receptors and by inhibition of calcium channels. In a clinical trial, clopimozide exhibited a marked effect on schizophrenic target symptoms, with an absence of sedation and a low degree of extrapyramidal side-effects. Despite positive results, the drug was never marketed.
